Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2024
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: 13 November 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digitally enabled therapy for chronic tic disorders and Tourette SyndromeStatus:In developmentProgramme:Medical technologies guidanceExpected publication date: TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children TSID 12001Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC